Core Insights - Surrozen is advancing targeted protein degradation (TPD) technologies to enhance Wnt-signal activation for treating liver diseases, specifically through the development of ASGR-targeted bispecific antibodies [1][7][10] - The company has initiated a Phase 1b clinical trial for SZN-043, focusing on severe alcohol-associated hepatitis, with proof-of-concept data expected in the first half of 2025 [3][9] Group 1: TPD Technologies and Research - The publication highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that activate Wnt signaling through a unique TPD platform, enhancing liver function in mouse models [1][8] - A review article published in iScience summarizes the progress in Wnt activating platforms, emphasizing the potential of Wnt agonists in treating tissue degenerative diseases [2] Group 2: Clinical Development - SZN-043 is the first candidate utilizing Surrozen's SWEETS technology, having completed a Phase 1a clinical trial demonstrating safety and target engagement [3][9] - The Phase 1b clinical trial for SZN-043 began enrollment in Q2 2024, with expectations for proof-of-concept data in early 2025 [9] Group 3: Company Overview - Surrozen is a clinical-stage biotechnology company focused on discovering and developing drug candidates that selectively modulate the Wnt pathway, targeting severe liver and eye diseases [5][10] - The company's proprietary technologies aim to overcome limitations in pursuing the Wnt pathway as a therapeutic strategy, with a focus on tissue-specific antibodies [10]
Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling